Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 22, 2026.

Chinese Stroke Association guidelines for clinical management of ischaemic cerebrovascular diseases: executive summary and 2023 update

Liping Liu, Zixiao Li, Hongyu Zhou and 16 more

Stroke and Vascular Neurology · 2023

doi:10.1136/svn-2023-002998

Abstract

Background. China is one of the countries with the highest burden of stroke. Implementing multidimensional management guidelines will help clinicians practise evidence-based care, improve patient outcomes and alleviate societal burdens. This update of the 2019 edition will provide the latest comprehensive recommendations for the diagnosis and treatment of ischaemic cerebrovascular diseases.

Methods. We conducted a comprehensive search on MEDLINE (via PubMed) up to 31 August 2023. The writing team established the recommendations through multiple rounds of online and offline discussions. Each recommendation was graded using the evidence grading algorithm developed by the Chinese Stroke Association (CSA). The draft was reviewed and finalised by the CSA Stroke Guidelines Writing Committee.

Results. This update included revisions of 15 existing recommendations and 136 new recommendations in the following areas of stroke care: emergency assessment and diagnosis of ischaemic cerebrovascular disease, acute-phase reperfusion therapy, evaluation of underlying mechanisms, antithrombotic therapy, prevention and treatment of complications, and risk factor management.

Conclusions. This guideline updated the recommendations for the clinical management of ischaemic cerebrovascular disease from 2019.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 22, 2026. Paragraph numbers are ours, so an answer can point at one.

Highlights

The clinical management of ischaemic cerebrovascular diseases comprises a total of 287 recommendations, including 136 new recommendations and 15 revised recommendations from the version in 2019. These highlights reflect significant new therapeutic options developed in recent times that will impact the daily management of patients with acute ischaemic stroke (AIS).

Reperfusion therapy

Tenecteplase (TNK) 0.25 mg/kg intravenous push has been proven non-inferior to intravenous standard dosage of recombinant tissue plasminogen activator (rt-PA) to treat patients with AIS with <4.5 hours of onset (Section 3.1).

For patients with anterior circulation large vessel occlusion (LVO) type of AIS who present within 4.5 hours of symptom onset, the efficacy of intravenous TNK (0.25 mg/kg) is non-inferior to intravenous rt-PA (0.9 mg/kg) before intra-arterial (IA) mechanical thrombectomy (MT). The TNK might offer better reperfusion outcomes, while the incidence of symptomatic intracerebral haemorrhage (sICH) remains similar (Section 3.1).

For patients with AIS with anterior circulation LVO and a large core infarct within 24 hours of onset and who meet the inclusion criteria of the RESCUE-Japan LIMIT, ANGEL-ASPECT and SELECT 2 trials, IA MT is recommended (Section 3.2).

For patients with acute basilar artery occlusion (BAO) within 6 hours of onset who meet the inclusion criteria of the ATTENTION trial, IA MT is recommended (Section 3.2).

Patients with acute BAO within 6–12 hours of onset are recommended for IA MT when they meet the inclusion criteria of the ATTENTION or BAOCHE trials (Section 3.2).

Patients with acute BAO within 12–24 hours of onset are recommended for MT when they meet the inclusion criteria of the BAOCHE trial (Section 3.2).

Antiplatelet therapy

Intravenous tirofiban can be beneficial in those patients who meet the RESCUE BT2 trial inclusion criteria (Section 4.1).

For patients with non-cardioembolic minor ischaemic stroke (IS) (National Institutes of Health Stroke Scale (NIHSS) score ≤3) or high-risk transient ischaemic attack (TIA) (ABCD2 score ≤4) who present within 24 hours of symptom onset, if CYP2C19 gene testing can be tested and the patient carries CYP2C19 loss-of-function (LoF) alleles, ticagrelor plus aspirin for 21 days (ticagrelor loading dose of 180 mg on the first day, followed by 90 mg two times per day) and continue with ticagrelor monotherapy (90 mg two times per day) for 90 days are recommended (Section 4.2).

For patients with moderate IS (NIHSS score of 4–5) who present within 24 hours of symptom onset, ticagrelor plus aspirin for 30 days (ticagrelor loading dose of 180 mg on the first day, followed by 90 mg two times per day) may reduce the risk of recurrent stroke and death within 30 days (Section 4.2).

Brain cytoprotection

Brain cytoprotection with edaravone dexborneol (intravenous 37.5 mg/dose, once every 12 hours, for 14 days) may improve clinical outcomes in patients with AIS (Section 5.1).

DL-3-n-butylphthalide (NBP), 25 mg, dissolved in 100 mL sodium chloride and given as intravenous injection two times per day for the first 14 days, followed by soft 0.2 g capsules of NBP three times a day for the next 76 days, may serve as an adjunct treatment to reperfusion therapy and have the potential to improve functional outcomes in patients with AIS (Section 5.1).

Risk factor management

For patients who cannot tolerate statins or have contraindications to statin therapy, the use of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors or ezetimibe may be considered (Section 9.2).

For patients with IS or TIA with fasting triglycerides (TG) ≥135 mg/dL (1.52 mmol/L), who have received moderate or high-intensity statin therapy, a glycated haemoglobin (HbA1c) level <10%, and no history of pancreatitis, atrial fibrillation, or severe heart failure, treatment with icosapent ethyl (2 g two times per day) can reduce the risk of stroke recurrence (Section 9.2).

Introduction

The incidence of stroke in the Chinese population continues to rise, accounting for nearly one-fourth of the global annual stroke cases. Among adults aged 40 years or above in China, IS accounted for approximately 86.8% of all strokes. Timely updates to the guidelines can provide new evidence-based recommendations for diagnosis, acute-phase treatment, prevention and management of complications, and secondary prevention for IS.

Since the publication of the 2019 Chinese Stroke Association (CSA) guidelines, notable advancements have emerged in acute-phase reperfusion therapy and antiplatelet treatments for secondary IS prevention. The findings of several high-quality randomised controlled trials (RCTs) conducted in China will have an impact on stroke care. Some new lipid-lowering agents are also helpful in stroke prevention.

We conducted a comprehensive search of MEDLINE (via PubMed) up to 31 August 2023, and compiled the relevant information into a tabular format. The writing team established the level of recommendation through multiple rounds of online and offline discussions. Each recommendation was graded using the evidence grading algorithm developed by the CSA (table 1). The updated guideline kept the nine sections: definitions, emergency assessment and diagnosis, reperfusion therapy, antiplatelet therapy, other treatments in the acute phase, general supportive treatment and management of complications, early evaluation of the aetiology and pathogenesis, interventions targeting aetiology and pathogenesis, risk factor management and long-term intervention.

Section 1: definitions associated with ischaemic cerebrovascular diseases

The definitions associated with ischaemic cerebrovascular diseases are shown in table 2.

Section 2: emergency assessment and diagnosis of patients with AIS

The acute care process for patients with AIS is shown in figure 1. The emergency diagnostic and examination process flow chart for patients with AIS is shown in figure 2.

Section 3: reperfusion therapy for AIS

The management process of intravenous thrombolysis for patients with AIS within 4.5 hours of symptom onset is shown in figure 3. The management process of intravenous thrombolysis for patients with AIS with an onset between 4.5 and 9 hours or wake-up stroke is shown in figure 4. The flow chart for IA MT in patients with AIS is shown in figure 5.

Section 4: antiplatelet therapy for acute ischaemic cerebrovascular disease

The antiplatelet treatment process for patients with AIS is shown in figure 6.

Section 6: general supportive treatment and management of complications

The management process for brain oedema/intracranial hypertension is shown in figure 7. The management process for haemorrhagic transformation in patients with AIS is shown in figure 8. The management process for the first seizure within 24 hours of stroke onset is shown in figure 9.

Section 7: early evaluation of aetiology and pathogenesis of ischaemic cerebrovascular disease

The diagnostic process for cryptogenic stroke is shown in figure 10.

Section 8: interventions targeting aetiology and pathogenesis

The treatment strategy for valvular heart disease is shown in figure 11.

Section 9: risk factor management and long-term intervention

The flow chart for blood pressure management within 72 hours after the onset of AIS is shown in figure 12. The flow chart for lipid-lowering management in patients with AIS is shown in figure 13. The flow chart for blood glucose management in patients with AIS is shown in figure 14.

References 290

  1. 1.
    Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 · 2021
    No notice
  2. 2.
    Estimated Burden of Stroke in China in 2020 · 2023
    No notice
  3. 3.

    Li Z, Jiang Y, Li H, et al. China’s response to the rising stroke burden. BMJ 2019;364:l879.

    Not in our library10.1136/bmj.l879

  4. 4.

    Tao C, Nogueira RG, Zhu Y, et al. Trial of endovascular treatment of acute basilar-artery occlusion. N Engl J Med 2022;387:1361–72.

    Not in our library10.1056/nejmoa2206317

  5. 5.

    Jovin TG, Li C, Wu L, et al. Trial of thrombectomy 6 to 24 hours after stroke due to basilar-artery occlusion. N Engl J Med 2022;387:1373–84.

    Not in our library10.1056/nejmoa2207576

  6. 6.

    Wang Y, Meng X, Wang A, et al. Ticagrelor versus Clopidogrel in cyp2C19 loss-of-function carriers with stroke or Tia. N Engl J Med 2021;385:2520–30.

    Not in our library10.1056/nejmoa2111749

  7. 7.

    Gerschenfeld G, Liegey J-S, Laborne F-X, et al. Treatment times, functional outcome, and hemorrhage rates after switching to tenecteplase for stroke thrombolysis: insights from the Tetris Registry. Eur Stroke J 2022;7:358–64.

    Not in our library10.1177/23969873221113729

  8. 8.

    Lees KR, Emberson J, Blackwell L, et al. Effects of alteplase for acute stroke on the distribution of functional outcomes: a pooled analysis of 9 trials. Stroke 2016;47:2373–9.

    Not in our library10.1161/strokeaha.116.013644

  9. 9.

    Campbell BCV, Ma H, Parsons MW, et al. Association of reperfusion after thrombolysis with clinical outcome across the 4.5- to 9-hours and wake-up stroke time window: a meta-analysis of the extend and epithet randomized clinical trials. JAMA Neurol 2021;78:236–40.

    Not in our library10.1001/jamaneurol.2020.4123

  10. 10.

    Goyal M, Almekhlafi M, Dippel DW, et al. Rapid alteplase administration improves functional outcomes in patients with stroke due to large vessel occlusions. Stroke 2019;50:645–51.

    Not in our library10.1161/strokeaha.118.021840

  11. 11.

    Fonarow GC, Zhao X, Smith EE, et al. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. JAMA 2014;311:1632–40.

    Not in our library10.1001/jama.2014.3203

  12. 12.

    Zaidi SF, Shawver J, Espinosa Morales A, et al. Stroke care: initial data from a county-based bypass protocol for patients with acute stroke. J Neurointerv Surg 2017;9:631–5.

    Not in our library10.1136/neurintsurg-2016-012476

  13. 13.

    Patel SC, Levine RS, Tilley BC. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA 2001;286:2830–8.

    Not in our library10.1001/jama.286.22.2830

  14. 14.

    Barber PA, Demchuk AM, Zhang J, et al. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. Lancet 2000;355:1670–4.

    Not in our library10.1016/s0140-6736(00)02237-6

  15. 15.

    Kalafut MA, Schriger DL, Saver JL, et al. Detection of early ct signs of >1/3 middle cerebral artery Infarctions: interrater reliability and sensitivity of ct interpretation by physicians involved in acute stroke care. Stroke 2000;31:1667–71.

    Not in our library10.1161/01.str.31.7.1667

  16. 16.

    Larrue V, von Kummer R, del Zoppo G, et al. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European cooperative acute stroke study. Stroke 1997;28:957–60.

    Not in our library10.1161/01.str.28.5.957

  17. 17.

    Thomalla G, Simonsen CZ, Boutitie F, et al. Mri-guided thrombolysis for stroke with unknown time of onset. N Engl J Med 2018;379:611–22.

    Not in our library10.1056/nejmoa1804355

  18. 18.

    Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med 2018;378:11–21.

    Not in our library10.1056/nejmoa1706442

  19. 19.

    Schwamm LH, Wu O, Song SS, et al. Intravenous thrombolysis in unwitnessed stroke onset: Mr witness trial results. Ann Neurol 2018;83:980–93.

    Not in our library10.1002/ana.25235

  20. 20.

    Chalela JA, Kidwell CS, Nentwich LM, et al. Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. Lancet 2007;369:293–8.

    Not in our library10.1016/s0140-6736(07)60151-2

  21. 21.

    Kidwell CS, Chalela JA, Saver JL, et al. Comparison of MRI and ct for detection of acute intracerebral hemorrhage. JAMA 2004;292:1823–30.

    Not in our library10.1001/jama.292.15.1823

  22. 22.

    Provost C, Soudant M, Legrand L, et al. Magnetic resonance imaging or computed tomography before treatment in acute ischemic stroke. Stroke 2019;50:659–64.

    Not in our library10.1161/strokeaha.118.023882

  23. 23.

    Menjot de Champfleur N, Saver JL, Goyal M, et al. Efficacy of Stent-retriever Thrombectomy in magnetic resonance imaging versus computed Tomographic perfusion-selected patients in swift prime trial (Solitaire FR with the intention for Thrombectomy as primary Endovascular treatment for acute ischemic stroke). Stroke 2017;48:1560–6.

    Not in our library10.1161/strokeaha.117.016669

  24. 24.

    Krebs S, Posekany A, Pilz A, et al. Ct- versus MRI-based imaging for thrombolysis and mechanical thrombectomy in ischemic stroke: analysis from the Austrian stroke Registry. J Stroke 2022;24:383–9.

    Not in our library10.5853/jos.2021.03846

  25. 25.

    Albers GW, Marks MP, Kemp S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med 2018;378:708–18.

    Not in our library10.1056/nejmoa1713973

  26. 26.

    Bash S, Villablanca JP, Jahan R, et al. Intracranial vascular stenosis and occlusive disease: evaluation with ct angiography, Mr angiography, and digital subtraction angiography. AJNR Am J Neuroradiol 2005;26:1012–21.

    Not in our library

  27. 27.

    Hirai T, Korogi Y, Ono K, et al. Prospective evaluation of suspected stenoocclusive disease of the intracranial artery: combined Mr angiography and CT angiography compared with Digital subtraction angiography. AJNR Am J Neuroradiol 2002;23:93–101.

    Not in our library

  28. 28.

    Jahan R, Saver JL, Schwamm LH, et al. Association between time to treatment with endovascular reperfusion therapy and outcomes in patients with acute ischemic stroke treated in clinical practice. JAMA 2019;322:252–63.

    Not in our library10.1001/jama.2019.8286

  29. 29.

    Grigoryan M, Haussen DC, Hassan AE, et al. Endovascular treatment of acute ischemic stroke due to tandem occlusions: large multicenter series and systematic review. Cerebrovasc Dis 2016;41:306–12.

    Not in our library10.1159/000444069

  30. 30.

    Olthuis SGH, Pirson FAV, Pinckaers FME, et al. Endovascular treatment versus no Endovascular treatment after 6-24 H in patients with ischaemic stroke and collateral flow on ct angiography (Mr clean-late) in the Netherlands: a multicentre, open-label, blinded-endpoint, randomised, controlled, phase 3 trial. Lancet 2023;401:1371–80.

    Not in our library10.1016/s0140-6736(23)00575-5

  31. 31.

    Liebeskind DS, Saber H, Xiang B, et al. Collateral circulation in thrombectomy for stroke after 6 to 24 hours in the dawn trial. Stroke 2022;53:742–8.

    Not in our library10.1161/strokeaha.121.034471

  32. 32.

    Rao VL, Mlynash M, Christensen S, et al. Collateral status contributes to differences between observed and predicted 24-H infarct volumes in defuse 3. J Cereb Blood Flow Metab 2020;40:1966–74.

    Not in our library10.1177/0271678x20918816

  33. 33.

    Tsivgoulis G, Zand R, Katsanos AH, et al. Risk of symptomatic intracerebral hemorrhage after intravenous Thrombolysis in patients with acute ischemic stroke and high cerebral Microbleed burden: a meta-analysis. JAMA Neurol 2016;73:675–83.

    Not in our library10.1001/jamaneurol.2016.0292

  34. 34.

    Zand R, Tsivgoulis G, Singh M, et al. Cerebral microbleeds and risk of intracerebral hemorrhage post intravenous thrombolysis. J Stroke Cerebrovasc Dis 2017;26:538–44.

    Not in our library10.1016/j.jstrokecerebrovasdis.2016.11.127

  35. 35.

    Charidimou A, Turc G, Oppenheim C, et al. Microbleeds, cerebral hemorrhage, and functional outcome after stroke thrombolysis. Stroke 2017;48:2084–90.

    Not in our library10.1161/strokeaha.116.012992

  36. 36.

    Wang S, Lv Y, Zheng X, et al. The impact of cerebral microbleeds on intracerebral hemorrhage and poor functional outcome of acute ischemic stroke patients treated with intravenous thrombolysis: a systematic review and meta-analysis. J Neurol 2017;264:1309–19.

    Not in our library10.1007/s00415-016-8339-1

  37. 37.

    Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–7.

    Not in our library10.1056/nejm199512143332401

  38. 38.

    Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317–29.

    Not in our library10.1056/nejmoa0804656

  39. 39.

    Jeong H-G, Kim BJ, Kim T, et al. Classification of cardioembolic stroke based on a deep neural network using chest radiographs. EBioMedicine 2021;69:103466.

    Not in our library10.1016/j.ebiom.2021.103466

  40. 40.

    Tokuda N, Koga M, Ohara T, et al. Urgent detection of acute type a aortic dissection in hyperacute ischemic stroke or transient ischemic attack. J Stroke Cerebrovasc Dis 2018;27:2112–7.

    Not in our library10.1016/j.jstrokecerebrovasdis.2018.03.010

  41. 41.

    Desilles J-P, Consoli A, Redjem H, et al. Successful reperfusion with mechanical thrombectomy is associated with reduced disability and mortality in patients with pretreatment diffusion-weighted imaging-Alberta stroke program early computed tomography score ≤6. Stroke 2017;48:963–9.

    Not in our library10.1161/strokeaha.116.015202

  42. 42.

    Berkhemer OA, Fransen PSS, Beumer D, et al. A randomized trial of Intraarterial treatment for acute ischemic stroke. N Engl J Med 2015;372:11–20.

    Not in our library10.1056/nejmoa1411587

  43. 43.

    Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 2015;372:1019–30.

    Not in our library10.1056/nejmoa1414905

  44. 44.

    Campbell BCV, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 2015;372:1009–18.

    Not in our library10.1056/nejmoa1414792

  45. 45.

    Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous t-PA vs. T-PA alone in stroke. N Engl J Med 2015;372:2285–95.

    Not in our library10.1056/nejmoa1415061

  46. 46.

    Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med 2015;372:2296–306.

    Not in our library10.1056/nejmoa1503780

  47. 47.

    Bracard S, Ducrocq X, Mas JL, et al. Mechanical thrombectomy after intravenous Alteplase versus Alteplase alone after stroke (Thrace): a randomised controlled trial. Lancet Neurol 2016;15:1138–47.

    Not in our library10.1016/s1474-4422(16)30177-6

  48. 48.

    Anderson CS, Robinson T, Lindley RI, et al. Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke. N Engl J Med 2016;374:2313–23.

    Not in our library10.1056/nejmoa1515510

  49. 49.

    Zheng H, Yang Y, Chen H, et al. Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: the first multicentre, phase III trial in China. Stroke Vasc Neurol 2020;5:285–90.

    Not in our library10.1136/svn-2020-000337

  50. 50.

    Bluhmki E, Danays T, Biegert G, et al. Alteplase for acute ischemic stroke in patients aged >80 years: pooled analyses of individual patient data. Stroke 2020;51:2322–31.

    Not in our library10.1161/strokeaha.119.028396

  51. 51.

    Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012;379:2364–72.

    Not in our library10.1016/s0140-6736(12)60738-7

  52. 52.

    Ma H, Campbell BCV, Parsons MW, et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. N Engl J Med 2019;380:1795–803.

    Not in our library10.1056/nejmoa1813046

  53. 53.

    Davis SM, Donnan GA, Parsons MW, et al. Effects of Alteplase beyond 3 H after stroke in the echoplanar imaging thrombolytic evaluation trial (epithet): a placebo-controlled randomised trial. Lancet Neurol 2008;7:299–309.

    Not in our library10.1016/s1474-4422(08)70044-9

  54. 54.

    Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European cooperative acute stroke study (ECASS). JAMA 1995;274:1017–25.

    Not in our library

  55. 55.

    IST-3 collaborative group, Sandercock P, Wardlaw JM, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 H of acute ischaemic stroke (the third International stroke trial [IST-3]): a randomised controlled trial. Lancet 2012;379:2352–63.

    Not in our library10.1016/s0140-6736(12)60768-5

  56. 56.

    Tsivgoulis G, Frey JL, Flaster M, et al. Pre-tissue plasminogen activator blood pressure levels and risk of symptomatic intracerebral hemorrhage. Stroke 2009;40:3631–4.

    Not in our library10.1161/strokeaha.109.564096

  57. 57.

    Campbell BCV, Mitchell PJ, Yan B, et al. A multicenter, randomized, controlled study to investigate extending the time for thrombolysis in emergency neurological deficits with intra-arterial therapy (extend-IA). Int J Stroke 2014;9:126–32.

    Not in our library10.1111/ijs.12206

  58. 58.

    Anderson CS, Huang Y, Lindley RI, et al. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (enchanted): an international, randomised, open-label, blinded-Endpoint, phase 3 trial. Lancet 2019;393:877–88.

    Not in our library10.1016/s0140-6736(19)30038-8

  59. 59.

    Li C, Wang Y, Chen Y, et al. Optimal blood pressure levels in patients undergoing intravenous thrombolysis for AIS. Minerva Med 2015;106:255–8.

    Not in our library

  60. 60.

    Jeong H-G, Kim BJ, Yang MH, et al. Stroke outcomes with use of antithrombotics within 24 hours after recanalization treatment. Neurology 2016;87:996–1002.

    Not in our library10.1212/wnl.0000000000003083

  61. 61.

    Zinkstok SM, Beenen LF, Majoie CB, et al. Early deterioration after thrombolysis plus aspirin in acute stroke: a post hoc analysis of the antiplatelet therapy in combination with recombinant t-PA thrombolysis in ischemic stroke trial. Stroke 2014;45:3080–2.

    Not in our library10.1161/strokeaha.114.006268

  62. 62.

    Zinkstok SM, Roos YB, ARTIS investigators. Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. Lancet 2012;380:731–7.

    Not in our library10.1016/s0140-6736(12)60949-0

  63. 63.

    Jung J-M, Kim HJ, Ahn H, et al. Chronic kidney disease and intravenous thrombolysis in acute stroke: a systematic review and meta-analysis. J Neurol Sci 2015;358:345–50.

    Not in our library10.1016/j.jns.2015.09.353

  64. 64.

    Malhotra K, Katsanos AH, Goyal N, et al. Intravenous thrombolysis in patients with chronic kidney disease: a systematic review and meta-analysis. Neurology 2020;95:e121–30.

    Not in our library10.1212/wnl.0000000000009756

  65. 65.

    Hao Z, Yang C, Liu M, et al. Renal dysfunction and thrombolytic therapy in patients with acute ischemic stroke: a systematic review and meta-analysis. Medicine (Baltimore) 2014;93:e286.

    Not in our library10.1097/md.0000000000000286

  66. 66.

    Cappellari M, Carletti M, Micheletti N, et al. Intravenous alteplase for acute ischemic stroke in patients with current malignant neoplasm. J Neurol Sci 2013;325:100–2.

    Not in our library10.1016/j.jns.2012.12.008

  67. 67.

    Karlinski M, Kobayashi A, Czlonkowska A, et al. Role of preexisting disability in patients treated with intravenous thrombolysis for ischemic stroke. Stroke 2014;45:770–5.

    Not in our library10.1161/strokeaha.113.003744

  68. 68.

    Foell RBT, Silver B, Merino JG, et al. Effects of thrombolysis for acute stroke in patients with pre-existing disability. CMAJ 2003;169:193–7.

    Not in our library

  69. 69.

    National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke RT-PA stroke study experience. Ann Emerg Med 2005;46:243–52.

    Not in our library10.1016/j.annemergmed.2005.02.013

  70. 70.

    Khatri P, Tayama D, Cohen G, et al. Effect of intravenous recombinant tissue-type plasminogen activator in patients with mild stroke in the third International stroke trial-3: post hoc analysis. Stroke 2015;46:2325–7.

    Not in our library10.1161/strokeaha.115.009951

  71. 71.

    Seners P, Perrin C, Lapergue B, et al. Bridging therapy or IV thrombolysis in minor stroke with large vessel occlusion. Ann Neurol 2020;88:160–9.

    Not in our library10.1002/ana.25756

  72. 72.

    Sykora M, Krebs S, Simader F, et al. Intravenous thrombolysis in stroke with admission Nihss score 0 or 1. Int J Stroke 2022;17:109–19.

    Not in our library10.1177/1747493021991969

  73. 73.

    Khatri P, Kleindorfer DO, Devlin T, et al. Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor Nondisabling neurologic deficits: the Prisms randomized clinical trial. JAMA 2018;320:156–66.

    Not in our library10.1001/jama.2018.8496

  74. 74.

    Romano JG, Gardener H, Campo-Bustillo I, et al. The mild and rapidly improving stroke study (Mariss): rationale and design. Int J Stroke 2019;14:983–6.

    Not in our library10.1177/1747493019873595

  75. 75.

    Zhang R, Wei H, Ren Y, et al. Outcomes and treatment complications of intravenous urokinase thrombolysis in acute ischemic stroke in China. Front Neurol 2021;12:685454.

    Not in our library10.3389/fneur.2021.685454

  76. 76.

    Kvistad CE, Næss H, Helleberg BH, et al. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (nor-test 2, part a): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial. Lancet Neurol 2022;21:511–9.

    Not in our library10.1016/s1474-4422(22)00124-7

  77. 77.

    Bivard A, Zhao H, Churilov L, et al. Comparison of tenecteplase with Alteplase for the early treatment of ischaemic stroke in the Melbourne mobile stroke unit (taste-a): a phase 2, randomised, open-label trial. Lancet Neurol 2022;21:520–7.

    Not in our library10.1016/s1474-4422(22)00171-5

  78. 78.

    Menon BK, Buck BH, Singh N, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (act): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet 2022;400:161–9.

    Not in our library10.1016/s0140-6736(22)01054-6

  79. 79.

    Wang Y, Li S, Pan Y, et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (Trace-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial. Lancet 2023;401:645–54.

    Not in our library10.1016/s0140-6736(22)02600-9

  80. 80.

    Campbell BC, Mitchell PJ, Churilov L, et al. Tenecteplase versus alteplase before endovascular thrombectomy (extend-IA Tnk): a multicenter, randomized, controlled study. Int J Stroke 2018;13:328–34.

    Not in our library10.1177/1747493017733935

  81. 81.

    Coutts SB, Dubuc V, Mandzia J, et al. Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion. Stroke 2015;46:769–74.

    Not in our library10.1161/strokeaha.114.008504

  82. 82.

    Yoshimura S, Sakai N, Yamagami H, et al. Endovascular therapy for acute stroke with a large ischemic region. N Engl J Med 2022;386:1303–13.

    Not in our library10.1056/nejmoa2118191

  83. 83.

    Huo X, Ma G, Tong X, et al. Trial of endovascular therapy for acute ischemic stroke with large infarct. N Engl J Med 2023;388:1272–83.

    Not in our library10.1056/nejmoa2213379

  84. 84.

    Sarraj A, Hassan AE, Abraham MG, et al. Trial of Endovascular Thrombectomy for large ischemic strokes. N Engl J Med 2023;388:1259–71.

    Not in our library10.1056/nejmoa2214403

  85. 85.

    Liu X, Dai Q, Ye R, et al. Endovascular treatment versus standard medical treatment for vertebrobasilar artery occlusion (best): an open-label, randomised controlled trial. Lancet Neurol 2020;19:115–22.

    Not in our library10.1016/s1474-4422(19)30395-3

  86. 86.

    Langezaal LCM, van der Hoeven EJRJ, Mont’Alverne FJA, et al. Endovascular therapy for stroke due to basilar-artery occlusion. N Engl J Med 2021;384:1910–20.

    Not in our library10.1056/nejmoa2030297

  87. 87.

    Renú A, Millán M, San Román L, et al. Effect of intra-arterial alteplase vs placebo following successful thrombectomy on functional outcomes in patients with large vessel occlusion acute ischemic stroke: the choice randomized clinical trial. JAMA 2022;327:826–35.

    Not in our library10.1001/jama.2022.1645

  88. 88.

    Huang Y, Cheng Y, Wu J, et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol 2008;7:494–9.

    Not in our library10.1016/s1474-4422(08)70094-2

  89. 89.

    Uchiyama S. Results of the cilostazol stroke prevention study II (Csps II): a randomized controlled trial for the comparison of cilostazol and aspirin in stroke patients. Rinsho Shinkeigaku 2010;50:832–4.

    Not in our library10.5692/clinicalneurol.50.832

  90. 90.

    Pan Y, Meng X, Yuan B, et al. Indobufen versus aspirin in patients with acute ischaemic stroke in China (insure): a randomised, double-blind, double-dummy, active control, non-inferiority trial. Lancet Neurol 2023;22:485–93.

    Not in our library10.1016/s1474-4422(23)00113-8

  91. 91.

    RESCUE BT Trial Investigators, Qiu Z, Li F, et al. Effect of intravenous tirofiban vs placebo before endovascular thrombectomy on functional outcomes in large vessel occlusion stroke: the rescue BT randomized clinical trial. JAMA 2022;328:543–53.

    Not in our library10.1001/jama.2022.12584

  92. 92.

    Zi W, Song J, Kong W, et al. Tirofiban for stroke without large or medium-sized vessel occlusion. N Engl J Med 2023;388:2025–36.

    Not in our library10.1056/nejmoa2214299

  93. 93.

    Wang Y, Zhao X, Lin J, et al. Association between Cyp2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA 2016;316:70–8.

    Not in our library10.1001/jama.2016.8662

  94. 94.

    Wang Y, Chen W, Lin Y, et al. Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial. BMJ 2019;365:l2211.

    Not in our library10.1136/bmj.l2211

  95. 95.

    Wang Y, Pan Y, Li H, et al. Efficacy and safety of ticagrelor and aspirin in patients with moderate ischemic stroke: an exploratory analysis of the Thales randomized clinical trial. JAMA Neurol 2021;78:1091–8.

    Not in our library10.1001/jamaneurol.2021.2440

  96. 96.

    Miyaji Y, Yoshimura S, Sakai N, et al. Effect of edaravone on favorable outcome in patients with acute cerebral large vessel occlusion: subanalysis of rescue-Japan Registry. Neurol Med Chir(Tokyo) 2015;55:241–7.

    Not in our library10.2176/nmc.ra.2014-0219

  97. 97.

    Xu J, Wang A, Meng X, et al. Edaravone dexborneol versus edaravone alone for the treatment of acute ischemic stroke: a phase III, randomized, double-blind, comparative trial. Stroke 2021;52:772–80.

    Not in our library10.1161/strokeaha.120.031197

  98. 98.

    Wang A, Jia B, Zhang X, et al. Efficacy and safety of Butylphthalide in patients with acute ischemic stroke: a randomized clinical trial. JAMA Neurol 2023;80:851–9.

    Not in our library10.1001/jamaneurol.2023.1871

  99. 99.

    England TJ, Hedstrom A, O’Sullivan S, et al. Recast (remote ischemic conditioning after stroke trial): a pilot randomized placebo controlled phase II trial in acute ischemic stroke. Stroke 2017;48:1412–5.

    Not in our library10.1161/strokeaha.116.016429

  100. 100.

    Chen H-S, Cui Y, Li X-Q, et al. Effect of remote ischemic conditioning vs usual care on neurologic function in patients with acute moderate ischemic stroke: the Ricamis randomized clinical trial. JAMA 2022;328:627–36.

    Not in our library10.1001/jama.2022.13123

  101. 101.

    Landman TR, Schoon Y, Warlé MC, et al. The effect of repeated remote ischemic Postconditioning after an ischemic stroke (Repost): a randomized controlled trial. Int J Stroke 2023;18:296–303.

    Not in our library10.1177/17474930221104710

  102. 102.

    Lapchak PA. Taking a light approach to treating acute ischemic stroke patients: transcranial near-infrared laser therapy translational science. Ann Med 2010;42:576–86.

    Not in our library10.3109/07853890.2010.532811

  103. 103.

    Stemer AB, Huisa BN, Zivin JA. The evolution of transcranial laser therapy for acute ischemic stroke, including a pooled analysis of Nest-1 and Nest-2. Curr Cardiol Rep 2010;12:29–33.

    Not in our library10.1007/s11886-009-0071-3

  104. 104.

    Zivin JA, Albers GW, Bornstein N, et al. Effectiveness and safety of transcranial laser therapy for acute ischemic stroke. Stroke 2009;40:1359–64.

    Not in our library10.1161/strokeaha.109.547547

  105. 105.

    Hacke W, Schellinger PD, Albers GW, et al. Transcranial laser therapy in acute stroke treatment: results of neurothera effectiveness and safety trial 3, a phase III clinical end point device trial. Stroke 2014;45:3187–93.

    Not in our library10.1161/strokeaha.114.005795

  106. 106.

    Khedr EM, Abdel‐Fadeil MR, Farghali A, et al. Role of 1 and 3 Hz repetitive transcranial magnetic stimulation on motor function recovery after acute ischaemic stroke. Euro J of Neurology 2009;16:1323–30. Available: https://onlinelibrary.wiley.com/toc/14681331/16/12

    Not in our library10.1111/j.1468-1331.2009.02746.x

  107. 107.
    Effects of rTMS Treatment on Cognitive Impairment and Resting-State Brain Activity in Stroke Patients: A Randomized Clinical Trial · 2020
    No notice
  108. 108.

    Smith EE, Kent DM, Bulsara KR, et al. Effect of Dysphagia screening strategies on clinical outcomes after stroke: a systematic review for the 2018 guidelines for the early management of patients with acute ischemic stroke. Stroke 2018;49:e123–8.

    Not in our library10.1161/str.0000000000000159

  109. 109.

    Rai N, Prasad K, Bhatia R, et al. Development and implementation of acute stroke care pathway in a tertiary care hospital in India: a cluster-randomized study. Neurol India 2016;64 Suppl:S39–45.

    Not in our library10.4103/0028-3886.178038

  110. 110.

    Middleton S, McElduff P, Ward J, et al. Implementation of evidence-based treatment protocols to manage fever, hyperglycaemia, and swallowing dysfunction in acute stroke (Qasc): a cluster randomised controlled trial. The Lancet 2011;378:1699–706.

    Not in our library10.1016/s0140-6736(11)61485-2

  111. 111.

    Miles A, Zeng ISL, McLauchlan H, et al. Cough reflex testing in dysphagia following stroke: a randomized controlled trial. J Clin Med Res 2013;5:222–33.

    Not in our library10.4021/jocmr1340w

  112. 112.

    Joundi RA, Martino R, Saposnik G, et al. Predictors and outcomes of dysphagia screening after acute ischemic stroke. Stroke 2017;48:900–6.

    Not in our library10.1161/strokeaha.116.015332

  113. 113.

    McCullough GH, Rosenbek JC, Wertz RT, et al. Utility of clinical swallowing examination measures for detecting aspiration post-stroke. J Speech Lang Hear Res 2005;48:1280–93.

    Not in our library10.1044/1092-43882005/089

  114. 114.

    Garon BR, Sierzant T, Ormiston C. Silent aspiration: results of 2,000 video fluoroscopic evaluations. J Neurosci Nurs 2009;41:178–85; quiz 86-7;

    Not in our library

  115. 115.

    Bingjie L, Tong Z, Xinting S, et al. Quantitative Videofluoroscopic analysis of penetration-aspiration in post-stroke patients. Neurol India 2010;58:42–7.

    Not in our library10.4103/0028-3886.60395

  116. 116.

    Cherney LR, Erickson RK, Small SL. Epidural cortical stimulation as adjunctive treatment for non-fluent aphasia: preliminary findings. J Neurol Neurosurg Psychiatry 2010;81:1014–21.

    Not in our library10.1136/jnnp.2009.184036

  117. 117.

    Nobis-Bosch R, Springer L, Radermacher I, et al. Supervised home training of dialogue skills in chronic aphasia: a randomized parallel group study. J Speech Lang Hear Res 2011;54:1118–36.

    Not in our library10.1044/1092-43882010/09-0204

  118. 118.

    Palmer R, Enderby P, Cooper C, et al. Computer therapy compared with usual care for people with long-standing aphasia poststroke: a pilot randomized controlled trial. Stroke 2012;43:1904–11.

    Not in our library10.1161/strokeaha.112.650671

  119. 119.

    National Collaborating Centre for Chronic Conditions (UK). Stroke: National clinical guideline for diagnosis and initial management of acute stroke and transient ischaemic attack (tia). London: National Institute for Health and Clinical Excellence: Guidance, 2008.

    Not in our library

  120. 120.

    Hinchey JA, Shephard T, Furie K, et al. Formal dysphagia screening protocols prevent pneumonia. Stroke 2005;36:1972–6.

    Not in our library10.1161/01.str.0000177529.86868.8d

  121. 121.

    Spyropoulos AC, Ageno W, Albers GW, et al. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N Engl J Med 2018;379:1118–27.

    Not in our library10.1056/nejmoa1805090

  122. 122.

    Valeriani E, Potere N, Candeloro M, et al. Extended venous thromboprophylaxis in patients hospitalized for acute ischemic stroke: a systematic review and meta-analysis. Eur J Intern Med 2022;95:80–6.

    Not in our library10.1016/j.ejim.2021.09.016

  123. 123.

    Larsson D, Baftiu A, Johannessen Landmark C, et al. Association between antiseizure drug monotherapy and mortality for patients with poststroke epilepsy. JAMA Neurol 2022;79:169–75.

    Not in our library10.1001/jamaneurol.2021.4584

  124. 124.

    Galovic M, Döhler N, Erdélyi-Canavese B, et al. Prediction of late seizures after ischaemic stroke with a novel prognostic model (the select score): a multivariable prediction model development and validation study. Lancet Neurol 2018;17:143–52.

    Not in our library10.1016/s1474-4422(17)30404-0

  125. 125.

    Katsanos AH, Bhole R, Frogoudaki A, et al. The value of transesophageal echocardiography for embolic strokes of undetermined source. Neurology 2016;87:988–95.

    Not in our library10.1212/wnl.0000000000003063

  126. 126.

    Mazzucco S, Li L, Binney L, et al. Prevalence of patent Foramen Ovale in Cryptogenic transient ischaemic attack and non-disabling stroke at older ages: a population-based study, systematic review, and meta-analysis. Lancet Neurol 2018;17:609–17.

    Not in our library10.1016/s1474-4422(18)30167-4

  127. 127.

    American Diabetes Association. 2. classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care 2020;43:S14–31.

    Not in our library10.2337/dc20-s002

  128. 128.

    Hoshino H, Toyoda K, Omae K, et al. Dual antiplatelet therapy using cilostazol with aspirin or clopidogrel: subanalysis of the Csps.com trial. Stroke 2021;52:3430–9.

    Not in our library10.1161/strokeaha.121.034378

  129. 129.

    Gao P, Wang T, Wang D, et al. Effect of Stenting plus medical therapy vs medical therapy alone on risk of stroke and death in patients with symptomatic intracranial stenosis: the Cassiss randomized clinical trial. JAMA 2022;328:534–42.

    Not in our library10.1001/jama.2022.12000

  130. 130.

    Zaidat OO, Fitzsimmons B-F, Woodward BK, et al. Effect of a balloon-expandable intracranial Stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the Vissit randomized clinical trial. JAMA 2015;313:1240–8.

    Not in our library10.1001/jama.2015.1693

  131. 131.

    Miao Z, Jiang L, Wu H, et al. Randomized controlled trial of symptomatic middle cerebral artery stenosis. Stroke 2012;43:3284–90.

    Not in our library10.1161/strokeaha.112.662270

  132. 132.

    Derdeyn CP, Chimowitz MI, Lynn MJ, et al. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (Sammpris): the final results of a randomised trial. Lancet 2014;383:333–41.

    Not in our library10.1016/s0140-6736(13)62038-3

  133. 133.

    Kasner SE, Chimowitz MI, Lynn MJ, et al. Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. Circulation 2006;113:555–63.

    Not in our library10.1161/circulationaha.105.578229

  134. 134.

    EC/IC BSG. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. N Engl J Med 1985;313:1191–200.

    Not in our library10.1056/nejm198511073131904

  135. 135.

    Rothwell P, Eliasziw M, Gutnikov S, et al. Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. The Lancet 2003;361:107–16.

    Not in our library10.1016/s0140-6736(03)12228-3

  136. 136.

    Yadav JS, Wholey MH, Kuntz RE, et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 2004;351:1493–501.

    Not in our library10.1056/nejmoa040127

  137. 137.

    Mas J-L, Chatellier G, Beyssen B, et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med 2006;355:1660–71.

    Not in our library10.1056/nejmoa061752

  138. 138.

    Eckstein H-H, Ringleb P, Allenberg J-R, et al. Results of the stent-protected angioplasty versus carotid endarterectomy (space) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial. Lancet Neurol 2008;7:893–902.

    Not in our library10.1016/s1474-4422(08)70196-0

  139. 139.

    Brott TG, Hobson RW, Howard G, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010;363:11–23.

    Not in our library10.1056/nejmoa0912321

  140. 140.

    International Carotid Stenting Study investigators, Ederle J, Dobson J, et al. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International carotid stenting study): an interim analysis of a randomised controlled trial. Lancet 2010;375:985–97.

    Not in our library10.1016/s0140-6736(10)60239-5

  141. 141.

    Warlow C. Mrc European carotid surgery trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. Lancet 1991;337:1235–43.

    Not in our library10.1016/0140-6736(91)92916-p

  142. 142.

    North American Symptomatic Carotid Endarterectomy Trial Collaborators, Barnett HJM, Taylor DW, et al. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991;325:445–53.

    Not in our library10.1056/nejm199108153250701

  143. 143.

    Mayberg MR, Wilson SE, Yatsu F, et al. Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis. Veterans affairs cooperative studies program 309 Trialist group. JAMA 1991;266:3289–94.

    Not in our library

  144. 144.

    Howard G, Roubin GS, Jansen O, et al. Association between age and risk of stroke or death from carotid endarterectomy and carotid stenting: a meta-analysis of pooled patient data from four randomised trials. Lancet 2016;387:1305–11.

    Not in our library10.1016/s0140-6736(15)01309-4

  145. 145.

    Rothwell PM, Eliasziw M, Gutnikov SA, et al. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 2004;363:915–24.

    Not in our library10.1016/s0140-6736(04)15785-1

  146. 146.

    Amarenco P, Kim JS, Labreuche J, et al. A comparison of two LDL cholesterol targets after ischemic stroke. N Engl J Med 2020;382:9.

    Not in our library10.1056/nejmoa1910355

  147. 147.

    Powers WJ, Clarke WR, Grubb RL, et al. Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia: the carotid occlusion surgery study randomized trial. JAMA 2011;306:1983–92.

    Not in our library10.1001/jama.2011.1610

  148. 148.

    Ma Y, Wang T, Wang H, et al. Extracranial-intracranial bypass and risk of stroke and death in patients with symptomatic artery occlusion: the Cmoss randomized clinical trial. JAMA 2023;330:704–14.

    Not in our library10.1001/jama.2023.13390

  149. 149.

    Di Tullio MR, Sacco RL, Homma S. Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. N Engl J Med 1996;335:1464.

    Not in our library10.1056/nejm199611073351913

  150. 150.

    Byrne C, Tawfick W, Hynes N, et al. Ten-year experience in subclavian revascularisation. A parallel comparative observational study. Vascular 2016;24:378–82.

    Not in our library10.1177/1708538115599699

  151. 151.

    Law MM, Colburn MD, Moore WS, et al. Carotid-subclavian bypass for Brachiocephalic occlusive disease. Choice of conduit and long-term follow-up. Stroke 1995;26:1565–71.

    Not in our library10.1161/01.str.26.9.1565

  152. 152.

    Chang JB, Stein TA, Liu JP, et al. Long-term results with Axillo-Axillary bypass grafts for symptomatic subclavian artery insufficiency. J Vasc Surg 1997;25:173–8.

    Not in our library10.1016/s0741-5214(97)70335-5

  153. 153.

    Henry M, Henry I, Polydorou A, et al. Percutaneous transluminal angioplasty of the subclavian arteries. Int Angiol 2007;26:324–40.

    Not in our library

  154. 154.

    Reddy VY, Sievert H, Halperin J, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA 2014;312:1988–98.

    Not in our library10.1001/jama.2014.15192

  155. 155.

    Reddy VY, Doshi SK, Kar S, et al. 5-year outcomes after left atrial appendage closure: from the prevail and protect Af trials. J Am Coll Cardiol 2017;70:2964–75.

    Not in our library10.1016/j.jacc.2017.10.021

  156. 156.

    Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009;374:534–42.

    Not in our library10.1016/s0140-6736(09)61343-x

  157. 157.

    Holmes DR, Kar S, Price MJ, et al. Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy. J Am Coll Cardiol 2014;64:1–12.

    Not in our library10.1016/j.jacc.2014.04.029

  158. 158.

    Siontis KC, Zhang X, Eckard A, et al. Outcomes associated with Apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation 2018;138:1519–29.

    Not in our library10.1161/circulationaha.118.035418

  159. 159.

    Brembilla-Perrot B, Girerd N, Sellal JM, et al. Risk of atrial fibrillation after atrial flutter ablation: impact of AF history, gender, and antiarrhythmic drug medication. J Cardiovasc Electrophysiol 2014;25:813–20.

    Not in our library10.1111/jce.12413

  160. 160.

    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the heart rhythm society. Circulation 2014;130:e199–267.

    Not in our library10.1161/cir.0000000000000041

  161. 161.

    Russo A, Grigioni F, Avierinos J-F, et al. Thromboembolic complications after surgical correction of mitral regurgitation incidence, predictors, and clinical implications. J Am Coll Cardiol 2008;51:1203–11.

    Not in our library10.1016/j.jacc.2007.10.058

  162. 162.

    Sundt TM, Zehr KJ, Dearani JA, et al. Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement. J Thorac Cardiovasc Surg 2005;129:1024–31.

    Not in our library10.1016/j.jtcvs.2004.11.028

  163. 163.

    Makkar RR, Fontana G, Jilaihawi H, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med 2015;373:2015–24.

    Not in our library10.1056/nejmoa1509233

  164. 164.

    Nuñez L, Gil Aguado M, Larrea JL, et al. Prevention of thromboembolism using aspirin after mitral valve replacement with porcine Bioprosthesis. Ann Thorac Surg 1984;37:84–7.

    Not in our library10.1016/s0003-4975(10)60717-5

  165. 165.

    Heras M, Chesebro JH, Fuster V, et al. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 1995;25:1111–9.

    Not in our library10.1016/0735-1097(94)00563-6

  166. 166.

    Colli A, Mestres CA, Castella M, et al. Comparing warfarin to aspirin (Woa) after aortic valve replacement with the St. Jude medical epic heart valve bioprosthesis: results of the Woa epic pilot trial. J Heart Valve Dis 2007;16:667–71.

    Not in our library

  167. 167.

    Otto CM, Nishimura RA, Bonow RO, et al. Acc/Aha guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 2021;143:e72–227.

    Not in our library10.1161/cir.0000000000000923

  168. 168.

    Whitlock RP, Sun JC, Fremes SE, et al. Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice guidelines. Chest 2012;141:e576S–e600S.

    Not in our library10.1378/chest.11-2305

  169. 169.

    Barsic B, Dickerman S, Krajinovic V, et al. Influence of the timing of cardiac surgery on the outcome of patients with infective endocarditis and stroke. Clin Infect Dis 2013;56:209–17.

    Not in our library10.1093/cid/cis878

  170. 170.

    Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369:1206–14.

    Not in our library10.1056/nejmoa1300615

  171. 171.

    Vaitkus PT, Barnathan ES. Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: a meta-analysis. J Am Coll Cardiol 1993;22:1004–9.

    Not in our library10.1016/0735-1097(93)90409-t

  172. 172.

    Lee JM, Park JJ, Jung HW, et al. Left ventricular thrombus and subsequent thromboembolism, comparison of anticoagulation, surgical removal, and antiplatelet agents. J Atheroscler Thromb 2013;20:73–93.

    Not in our library10.5551/jat.13540

  173. 173.

    Fleddermann AM, Hayes CH, Magalski A, et al. Efficacy of direct acting oral anticoagulants in treatment of left ventricular thrombus. Am J Cardiol 2019;124:367–72.

    Not in our library10.1016/j.amjcard.2019.05.009

  174. 174.

    Robinson AA, Trankle CR, Eubanks G, et al. Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi. JAMA Cardiol 2020;5:685–92.

    Not in our library10.1001/jamacardio.2020.0652

  175. 175.

    Cho SM, Moazami N, Frontera JA. Stroke and intracranial hemorrhage in heartmate II and heartware left ventricular assist devices: a systematic review. Neurocrit Care 2017;27:17–25.

    Not in our library10.1007/s12028-017-0386-7

  176. 176.

    Andreas M, Moayedifar R, Wieselthaler G, et al. Increased thromboembolic events with dabigatran compared with vitamin K antagonism in left ventricular assist device patients. Circ Heart Fail 2017;10:e003709.

    Not in our library10.1161/circheartfailure.116.003709

  177. 177.

    Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent Foramen Ovale closure or medical therapy after stroke. N Engl J Med 2017;377:1022–32.

    Not in our library10.1056/nejmoa1610057

  178. 178.

    Mas J-L, Derumeaux G, Guillon B, et al. Patent Foramen Ovale closure or anticoagulation vs antiplatelets after stroke. N Engl J Med 2017;377:1011–21.

    Not in our library10.1056/nejmoa1705915

  179. 179.

    Søndergaard L, Kasner SE, Rhodes JF, et al. Patent Foramen Ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med 2017;377:1033–42.

    Not in our library10.1056/nejmoa1707404

  180. 180.

    Furlan AJ, Reisman M, Massaro J, et al. Closure or medical therapy for cryptogenic stroke with patent Foramen Ovale. N Engl J Med 2012;366:991–9.

    Not in our library10.1056/nejmoa1009639

  181. 181.

    Meier B, Kalesan B, Mattle HP, et al. Percutaneous closure of patent Foramen Ovale in cryptogenic embolism. N Engl J Med 2013;368:1083–91.

    Not in our library10.1056/nejmoa1211716

  182. 182.

    Carroll JD, Saver JL, Thaler DE, et al. Closure of patent Foramen Ovale versus medical therapy after cryptogenic stroke. N Engl J Med 2013;368:1092–100.

    Not in our library10.1056/nejmoa1301440

  183. 183.

    Messé SR, Gronseth GS, Kent DM, et al. Practice advisory update summary: patent Foramen Ovale and secondary stroke prevention: report of the guideline subcommittee of the American Academy of Neurology. Neurology 2020;94:876–85.

    Not in our library10.1212/wnl.0000000000009443

  184. 184.
    Ischemic Stroke in Children and Young Adults With Congenital Heart Disease · 2016
    Not checked
  185. 185.

    Lanz J, Brophy JM, Therrien J, et al. Stroke in adults with congenital heart disease: incidence, cumulative risk, and predictors. Circulation 2015;132:2385–94.

    Not in our library10.1161/circulationaha.115.011241

  186. 186.

    McRae ME. Long-term issues after the Fontan procedure. AACN Adv Crit Care 2013;24:264–82; quiz 83-4;

    Not in our library10.1097/nci.0b013e31829744c7

  187. 187.

    Tamin SS, Maleszewski JJ, Scott CG, et al. Prognostic and Bioepidemiologic implications of papillary Fibroelastomas. J Am Coll Cardiol 2015;65:2420–9.

    Not in our library10.1016/j.jacc.2015.03.569

  188. 188.

    Galli M, Capodanno D, Benenati S, et al. Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trials. Eur Heart J Cardiovasc Pharmacother 2022;8:519–28.

    Not in our library10.1093/ehjcvp/pvab043

  189. 189.

    Duncan PW, Bushnell CD, Rosamond WD, et al. The comprehensive post-acute stroke services (compass) study: design and methods for a cluster-randomized pragmatic trial. BMC Neurol 2017;17:133.

    Not in our library10.1186/s12883-017-0907-1

  190. 190.

    Sharma M, Molina CA, Toyoda K, et al. Rationale and design of the axiomatic-Ssp phase II trial: antithrombotic treatment with factor Xia inhibition to optimize management of acute thromboembolic events for secondary stroke prevention. J Stroke Cerebrovasc Dis 2022;31:106742.

    Not in our library10.1016/j.jstrokecerebrovasdis.2022.106742

  191. 191.

    Gotoh F, Tohgi H, Hirai S, et al. Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000;9:147–57.

    Not in our library10.1053/jscd.2000.7216

  192. 192.

    Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (Csps 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010;9:959–68.

    Not in our library10.1016/s1474-4422(10)70198-8

  193. 193.

    SPS3 I, Benavente O, Hart R. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012;367:817–25.

    Not in our library10.1056/nejmoa1204133

  194. 194.

    Spanos K, Karathanos C, Stamoulis K, et al. Endovascular treatment of traumatic internal carotid artery pseudoaneurysm. Injury 2016;47:307–12.

    Not in our library10.1016/j.injury.2015.09.015

  195. 195.

    Moon K, Albuquerque FC, Cole T, et al. Stroke prevention by endovascular treatment of carotid and vertebral artery dissections. J Neurointerv Surg 2017;9:952–7.

    Not in our library10.1136/neurintsurg-2016-012565

  196. 196.

    Arnold M, Bousser MG, Baumgartner RW. Prognosis and safety of anticoagulation in intracranial artery Dissections in adults. Stroke 2007;38:e140; author reply e141.

    Not in our library10.1161/strokeaha.107.497370

  197. 197.

    Debette S, Mazighi M, Bijlenga P, et al. Eso guideline for the management of extracranial and intracranial artery dissection. Eur Stroke J 2021;6:XXXIX–LXXXVIII.

    Not in our library10.1177/23969873211046475

  198. 198.

    Sikkema T, Uyttenboogaart M, Eshghi O, et al. Intracranial artery dissection. Eur J Neurol 2014;21:820–6.

    Not in our library10.1111/ene.12384

  199. 199.

    Kraemer M, Berlit P, Diesner F, et al. What is the expert’s option on antiplatelet therapy in Moyamoya disease? Results of a worldwide survey. Eur J Neurol 2012;19:163–7.

    Not in our library10.1111/j.1468-1331.2011.03481.x

  200. 200.

    Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007;56:2789–97.

    Not in our library10.1002/art.22754

  201. 201.

    Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med 2017;377:317–28.

    Not in our library10.1056/nejmoa1613849

  202. 202.

    Villiger PM, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2016;387:1921–7.

    Not in our library10.1016/s0140-6736(16)00560-2

  203. 203.

    Hoffman GS, Leavitt RY, Kerr GS, et al. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 1994;37:578–82.

    Not in our library10.1002/art.1780370420

  204. 204.

    de Souza AWS, de Almeida Agustinelli R, de Cinque Almeida H, et al. Leflunomide in Takayasu arteritis - a long term observational study. Rev Bras Reumatol Engl Ed 2016;56:371–5.

    Not in our library10.1016/j.rbre.2016.02.003

  205. 205.

    Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002;347:261–71.

    Not in our library10.1056/nejmra011913

  206. 206.

    Hellmich B, Agueda A, Monti S, et al. Update of the Eular recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2020;79:19–30.

    Not in our library10.1136/annrheumdis-2019-215672

  207. 207.

    Salvarani C, Brown RD, Christianson TJH, et al. Adult primary central nervous system vasculitis treatment and course: analysis of one hundred sixty-three patients. Arthritis Rheumatol 2015;67:1637–45.

    Not in our library10.1002/art.39068

  208. 208.

    Hutchinson C, Elbers J, Halliday W, et al. Treatment of small vessel primary CNS vasculitis in children: an open-label cohort study. Lancet Neurol 2010;9:1078–84.

    Not in our library10.1016/s1474-4422(10)70243-x

  209. 209.

    Lanthier S, Armstrong D, Domi T, et al. Post-varicella arteriopathy of childhood: natural history of vascular stenosis. Neurology 2005;64:660–3.

    Not in our library10.1212/01.wnl.0000151851.66154.27

  210. 210.

    Gutierrez J, Ortiz G. Hiv/AIDS patients with HIV vasculopathy and Vzv vasculitis: a case series. Clin Neuroradiol 2011;21:145–51.

    Not in our library10.1007/s00062-011-0087-0

  211. 211.

    Workowski KA. Centers for disease control and prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis 2015;61 Suppl 8:S759–62.

    Not in our library10.1093/cid/civ771

  212. 212.

    Benjamin LA, Allain TJ, Mzinganjira H, et al. The role of human immunodeficiency virus-associated vasculopathy in the etiology of stroke. J Infect Dis 2017;216:545–53.

    Not in our library10.1093/infdis/jix340

  213. 213.

    Goldstein DA, Timpone J, Cupps TR. Hiv-associated intracranial aneurysmal vasculopathy in adults. J Rheumatol 2010;37:226–33.

    Not in our library10.3899/jrheum.090643

  214. 214.

    Yap S, Naughten ER, Wilcken B, et al. Vascular complications of severe hyperhomocysteinemia in patients with Homocystinuria due to cystathionine beta-synthase deficiency: effects of homocysteine-lowering therapy. Semin Thromb Hemost 2000;26:335–40.

    Not in our library10.1055/s-2000-8100

  215. 215.

    El Dib R, Gomaa H, Carvalho RP, et al. Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev 2016;7:CD006663.

    Not in our library10.1002/14651858.cd006663.pub4

  216. 216.

    Zhang AJ, Dhruv P, Choi P, et al. A systematic literature review of patients with carotid web and acute ischemic stroke. Stroke 2018;49:2872–6.

    Not in our library10.1161/strokeaha.118.021907

  217. 217.

    Haussen DC, Grossberg JA, Koch S, et al. Multicenter experience with stenting for symptomatic carotid web. Interv Neurol 2018;7:413–8.

    Not in our library10.1159/000489710

  218. 218.

    Haussen DC, Grossberg JA, Bouslama M, et al. Carotid web (intimal fibromuscular dysplasia) has high stroke recurrence risk and is amenable to stenting. Stroke 2017;48:3134–7.

    Not in our library10.1161/strokeaha.117.019020

  219. 219.

    Kadian-Dodov D, Gornik HL, Gu X, et al. Dissection and aneurysm in patients with fibromuscular dysplasia. J Am Coll Cardiol 2016;68:176–85.

    Not in our library10.1016/j.jacc.2016.04.044

  220. 220.

    Weinberg I, Gu X, Giri J, et al. Anti-platelet and anti-hypertension medication use in patients with fibromuscular dysplasia: results from the United States Registry for Fibromuscular dysplasia. Vasc Med 2015;20:447–53.

    Not in our library10.1177/1358863x15584982

  221. 221.

    Smith LL, Smith DC, Killeen JD, et al. Operative balloon Angioplasty in the treatment of internal carotid artery fibromuscular dysplasia. J Vasc Surg 1987;6:482–7.

    Not in our library10.1067/mva.1987.avs0060482

  222. 222.

    Kadian-Dodov D, Gornik HL, Gu X, et al. Dissection and aneurysm in patients with fibromuscular dysplasia: findings from the U.S. Registry for FMD. J Am Coll Cardiol 2016;68:176–85.

    Not in our library10.1016/j.jacc.2016.04.044

  223. 223.

    Echiverri HC, Rubino FA, Gupta SR, et al. Fusiform aneurysm of the vertebrobasilar arterial system. Stroke 1989;20:1741–7.

    Not in our library10.1161/01.str.20.12.1741

  224. 224.

    Chen Z, Zhang S, Dai Z, et al. Recurrent risk of ischemic stroke due to vertebrobasilar dolichoectasia. BMC Neurol 2019;19:163.

    Not in our library10.1186/s12883-019-1400-9

  225. 225.

    Nojima J, Kuratsune H, Suehisa E, et al. Strong correlation between the prevalence of cerebral infarction and the presence of anti-Cardiolipin/Beta2-glycoprotein I and anti-Phosphatidylserine/prothrombin antibodies--Co-existence of these antibodies enhances ADP-induced platelet activation in vitro. Thromb Haemost 2004;91:967–76.

    Not in our library10.1160/th03-10-0608

  226. 226.

    Tektonidou MG, Andreoli L, Limper M, et al. Eular recommendations for the management of Antiphospholipid syndrome in adults. Ann Rheum Dis 2019;78:1296–304.

    Not in our library10.1136/annrheumdis-2019-215213

  227. 227.

    Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (Waps). J Thromb Haemost 2005;3:848–53.

    Not in our library10.1111/j.1538-7836.2005.01340.x

  228. 228.

    Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the Antiphospholipid antibody syndrome. N Engl J Med 2003;349:1133–8.

    Not in our library10.1056/nejmoa035241

  229. 229.

    Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018;132:1365–71.

    Not in our library10.1182/blood-2018-04-848333

  230. 230.

    Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med 2019;171:685–94.

    Not in our library10.7326/m19-0291

  231. 231.

    Dufrost V, Risse J, Reshetnyak T, et al. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. Autoimmun Rev 2018;17:1011–21.

    Not in our library10.1016/j.autrev.2018.04.009

  232. 232.

    Dardiotis E, Aloizou A-M, Markoula S, et al. Cancer-associated stroke: pathophysiology, detection and management (review). Int J Oncol 2019;54:779–96.

    Not in our library10.3892/ijo.2019.4669

  233. 233.

    Yang P, Zhu D, Xu X, et al. Efficacy and safety of oral anticoagulants in atrial fibrillation patients with cancer-a network meta-analysis. Heart Fail Rev 2020;25:823–31.

    Not in our library10.1007/s10741-019-09844-8

  234. 234.

    Harloff A, Schlachetzki F. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 2018;379:986–7.

    Not in our library10.1056/nejmc1809065

  235. 235.

    Toyoda K, Uchiyama S, Hagihara Y, et al. Dabigatran vs. aspirin for secondary prevention after embolic stroke of undetermined source - Japanese subanalysis of the re-SPECT Esus randomized controlled trial. Circ J 2020;84:2286–95.

    Not in our library10.1253/circj.cj-20-0563

  236. 236.

    Benavente OR, Coffey CS, Conwit R, et al. Blood-pressure targets in patients with recent Lacunar stroke: the SPS3 randomised trial. Lancet 2013;382:507–15.

    Not in our library10.1016/s0140-6736(13)60852-1

  237. 237.

    Kitagawa K, Yamamoto Y, Arima H, et al. Effect of Standard vs intensive blood pressure control on the risk of recurrent stroke: a randomized clinical trial and meta-analysis. JAMA Neurol 2019;76:1309–18.

    Not in our library10.1001/jamaneurol.2019.2167

  238. 238.

    Turan TN, Nizam A, Lynn MJ, et al. Relationship between risk factor control and vascular events in the Sammpris trial. Neurology 2017;88:379–85.

    Not in our library10.1212/wnl.0000000000003534

  239. 239.

    Liu L, Wang Z, Gong L, et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertens Res 2009;32:1032–40.

    Not in our library10.1038/hr.2009.139

  240. 240.

    Wiysonge CS, Bradley H, Mayosi BM, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2007:CD002003.

    Not in our library10.1002/14651858.cd002003.pub2

  241. 241.

    Bangalore S, Parkar S, Grossman E, et al. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007;100:1254–62.

    Not in our library10.1016/j.amjcard.2007.05.057

  242. 242.

    Bangalore S, Wild D, Parkar S, et al. Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis. J Am Coll Cardiol 2008;52:1062–72.

    Not in our library10.1016/j.jacc.2008.05.057

  243. 243.

    Amarenco P, Bogousslavsky J, Callahan A. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549–59.

    Not in our library10.1056/nejmoa061894

  244. 244.

    Callahan A, Amarenco P, Goldstein LB, et al. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the stroke prevention by aggressive reduction in cholesterol levels (Sparcl) trial. Arch Neurol 2011;68:1245–51.

    Not in our library10.1001/archneurol.2011.146

  245. 245.

    Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to Statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387–97.

    Not in our library10.1056/nejmoa1410489

  246. 246.

    Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713–22.

    Not in our library10.1056/nejmoa1615664

  247. 247.

    Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of Alirocumab vs Ezetimibe in Statin-intolerant patients, with a Statin rechallenge arm: the Odyssey alternative randomized trial. J Clin Lipidol 2015;9:758–69.

    Not in our library10.1016/j.jacl.2015.08.006

  248. 248.

    Chiavaroli L, Nishi SK, Khan TA, et al. Portfolio dietary pattern and cardiovascular disease: a systematic review and meta-analysis of controlled trials. Prog Cardiovasc Dis 2018;61:43–53.

    Not in our library10.1016/j.pcad.2018.05.004

  249. 249.

    Benner JS, Tierce JC, Ballantyne CM, et al. Follow-up lipid tests and physician visits are associated with improved adherence to Statin therapy. Pharmacoeconomics 2004;22 Suppl 3:13–23.

    Not in our library10.2165/00019053-200422003-00003

  250. 250.

    Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with Icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019;380:11–22.

    Not in our library10.1056/nejmoa1812792

  251. 251.

    Tanaka K, Ishikawa Y, Yokoyama M, et al. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the Jelis trial. Stroke 2008;39:2052–8.

    Not in our library10.1161/strokeaha.107.509455

  252. 252.

    Jia Q, Zhao X, Wang C, et al. Diabetes and poor outcomes within 6 months after acute ischemic stroke: the China National Stroke Registry. Stroke 2011;42:2758–62.

    Not in our library10.1161/strokeaha.111.621649

  253. 253.

    Jia Q, Liu G, Zheng H, et al. Impaired glucose regulation predicted 1-year mortality of Chinese patients with ischemic stroke: data from abnormal glucose regulation in patients with acute stroke across China. Stroke 2014;45:1498–500.

    Not in our library10.1161/strokeaha.113.002977

  254. 254.

    Jing J, Pan Y, Zhao X, et al. Insulin resistance and prognosis of nondiabetic patients with ischemic stroke: the across-China study (abnormal glucose regulation in patients with acute stroke across China). Stroke 2017;48:887–93.

    Not in our library10.1161/strokeaha.116.015613

  255. 255.

    Pan Y, Chen W, Wang Y. Prediabetes and outcome of ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis 2019;28:683–92.

    Not in our library10.1016/j.jstrokecerebrovasdis.2018.11.008

  256. 256.

    Rosella LC, Lebenbaum M, Fitzpatrick T, et al. Prevalence of prediabetes and undiagnosed diabetes in Canada (2007-2011) according to fasting plasma glucose and Hba1C screening criteria. Diabetes Care 2015;38:1299–305.

    Not in our library10.2337/dc14-2474

  257. 257.

    Nathan DM, Genuth S, Lachin J. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–86.

    Not in our library10.1056/nejm199309303291401

  258. 258.

    Intensive blood-glucose control with Sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) group. The Lancet 1998;352:837–53.

    Not in our library10.1016/s0140-6736(98)07019-6

  259. 259.

    Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–59.

    Not in our library10.1056/nejmoa0802743

  260. 260.

    Patel A, MacMahon S, Chalmers J. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560–72.

    Not in our library10.1056/nejmoa0802987

  261. 261.

    Li G, Zhang P, Wang J, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the DA Qing diabetes prevention study: a 23-year follow-up study. The Lancet Diabetes & Endocrinology 2014;2:474–80.

    Not in our library10.1016/s2213-8587(14)70057-9

  262. 262.

    Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403.

    Not in our library10.1056/nejmoa012512

  263. 263.

    Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes Association (ADA) and the European Association for the study of diabetes (EASD). Diabetes Care 2020;43:487–93.

    Not in our library10.2337/dci19-0066

  264. 264.

    Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes Association (Ada) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018;41:2669–701.

    Not in our library10.2337/dci18-0033

  265. 265.

    Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (Rewind): a double-blind, randomised placebo-controlled trial. The Lancet 2019;394:121–30.

    Not in our library10.1016/s0140-6736(19)31149-3

  266. 266.

    Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644–57.

    Not in our library10.1056/nejmoa1611925

  267. 267.

    Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 2016;374:1321–31.

    Not in our library10.1056/nejmoa1506930

  268. 268.

    Huang Z-X, Lin X-L, Lu H-K, et al. Lifestyles correlate with stroke recurrence in Chinese Inpatients with first-ever acute ischemic stroke. J Neurol 2019;266:1194–202.

    Not in our library10.1007/s00415-019-09249-5

  269. 269.

    Chen J, Li S, Zheng K, et al. Impact of smoking status on stroke recurrence. J Am Heart Assoc 2019;8:e011696.

    Not in our library10.1161/jaha.118.011696

  270. 270.

    Lin MP, Ovbiagele B, Markovic D, et al. Association of secondhand smoke with stroke outcomes. Stroke 2016;47:2828–35.

    Not in our library10.1161/strokeaha.116.014099

  271. 271.

    Thomas KH, Dalili MN, López-López JA, et al. Smoking cessation medicines and E-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol Assess 2021;25:1–224.

    Not in our library10.3310/hta25590

  272. 272.

    Guo K, Wang S, Shang X, et al. The effect of varenicline and bupropion on smoking cessation: a network meta-analysis of 20 randomized controlled trials. Addictive Behaviors 2022;131:107329.

    Not in our library10.1016/j.addbeh.2022.107329

  273. 273.

    Cinciripini PM, Kypriotakis G, Green C, et al. The effects of varenicline, bupropion, nicotine patch, and placebo on smoking cessation among Smokers with major depression: a randomized clinical trial. Depress Anxiety 2022;39:429–40.

    Not in our library10.1002/da.23259

  274. 274.

    King A, Vena A, de Wit H, et al. Effect of combination treatment with Varenicline and nicotine patch on smoking cessation among smokers who drink heavily: a randomized clinical trial. JAMA Netw Open 2022;5:e220951.

    Not in our library10.1001/jamanetworkopen.2022.0951

  275. 275.

    Billinger SA, Arena R, Bernhardt J, et al. Physical activity and exercise recommendations for stroke survivors: A statement for Healthcare professionals from the American heart Association/American Stroke Association. Stroke 2014;45:2532–53.

    Not in our library10.1161/str.0000000000000022

  276. 276.

    Biasin L, Sage MD, Brunton K, et al. Integrating aerobic training within subacute stroke rehabilitation: a feasibility study. Phys Ther 2014;94:1796–806.

    Not in our library10.2522/ptj.20130404

  277. 277.

    Lennon O, Carey A, Gaffney N, et al. A pilot randomized controlled trial to evaluate the benefit of the cardiac rehabilitation paradigm for the non-acute ischaemic stroke population. Clin Rehabil 2008;22:125–33.

    Not in our library10.1177/0269215507081580

  278. 278.

    Rackoll T, Nave AH, Ebinger M, et al. Physical fitness training in patients with subacute stroke (Phys-stroke): safety analyses of a randomized clinical trial. Int J Stroke 2022;17:93–100.

    Not in our library10.1177/17474930211006286

  279. 279.

    Nave AH, Rackoll T, Grittner U, et al. Physical fitness training in patients with subacute stroke (Phys-stroke): Multicentre, randomised controlled, Endpoint blinded trial. BMJ 2019:l5101.

    Not in our library10.1136/bmj.l5101

  280. 280.

    Wing RR, Bolin P, Brancati FL. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013;369:145–54.

    Not in our library10.1056/nejmoa1212914

  281. 281.

    Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (direct): an open-label, cluster-randomised trial. The Lancet 2018;391:541–51.

    Not in our library10.1016/s0140-6736(17)33102-1

  282. 282.

    LeBlanc ES, Patnode CD, Webber EM, et al. Behavioral and pharmacotherapy weight loss interventions to prevent obesity-related morbidity and mortality in adults: updated evidence report and systematic review for the us preventive services task force. JAMA 2018;320:1172–91.

    Not in our library10.1001/jama.2018.7777

  283. 283.

    Delgado-Lista J, Alcala-Diaz JF, Torres-Peña JD, et al. Long-term secondary prevention of cardiovascular disease with a mediterranean diet and a low-fat diet (Cordioprev): a randomised controlled trial. Lancet 2022;399:1876–85.

    Not in our library10.1016/s0140-6736(22)00122-2

  284. 284.

    Neal B, Wu Y, Feng X, et al. Effect of salt substitution on cardiovascular events and death. N Engl J Med 2021;385:1067–77.

    Not in our library10.1056/nejmoa2105675

  285. 285.

    Zhang G, Pan Y, Zhang R, et al. Prevalence and prognostic significance of malnutrition risk in patients with acute ischemic stroke: results from the third China National Stroke Registry. Stroke 2022;53:111–9.

    Not in our library10.1161/strokeaha.121.034366

  286. 286.

    Schuetz P, Fehr R, Baechli V, et al. Individualised nutritional support in medical Inpatients at nutritional risk: a randomised clinical trial. Lancet 2019;393:2312–21.

    Not in our library10.1016/s0140-6736(18)32776-4

  287. 287.

    Johansson T, Fowler P, Ek WE, et al. Oral contraceptives, hormone replacement therapy, and stroke risk. Stroke 2022;53:3107–15.

    Not in our library10.1161/strokeaha.121.038659

  288. 288.

    Li F, Zhu L, Zhang J, et al. Oral contraceptive use and increased risk of stroke: a dose-response meta-analysis of observational studies. Front Neurol 2019;10:993.

    Not in our library10.3389/fneur.2019.00993

  289. 289.

    Kim H, Jang D-K, Han Y-M, et al. Direct bypass versus indirect bypass in adult Moyamoya angiopathy with symptoms or hemodynamic instability: a meta-analysis of comparative studies. World Neurosurg 2016;94:273–84.

    Not in our library10.1016/j.wneu.2016.07.009

  290. 290.

    Jang D-K, Lee K-S, Rha HK, et al. Bypass surgery versus medical treatment for symptomatic Moyamoya disease in adults. J Neurosurg 2017;127:492–502.

    Not in our library10.3171/2016.8.jns152875

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.